Trial reportBMC psychiatry2013
Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression.
Trial report in BMC psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bipolar Research And Innovation Network - BRAIN
Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.The international journal of neuropsychopharmacology · 2020Pooled it
- Pooled it
- Aberrant resting-state functional network centrality and cognitive impairment in unmedicated, euthymic bipolar patients.BMC psychiatry · 2024Article
- Improvement of persistent impairments in executive functions and attention following electroconvulsive therapy in a case control longitudinal follow up study.BMC psychiatry · 2024Observational
- Heterogeneity of psychosocial functioning in patients with bipolar disorder: Associations with sociodemographic, clinical, neurocognitive and biochemical variables.Frontiers in psychiatry · 2022Article
- Neuropsychology of Bipolar Disorder.Current topics in behavioral neurosciences · 2021Article
- Executive Function Is Selectively Impaired in Old Age Bipolar Depression.Frontiers in psychology · 2017Article
- Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints.BMC psychiatry · 2016Article
- Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.The Journal of clinical psychiatry · 2015Article
- Options for pharmacological treatment of refractory bipolar depression.Current psychiatry reports · 2014Review
- Treatment-resistant bipolar depression: concepts and challenges for novel interventions.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe literature on the neuropsychological profiles in Bipolar disorder (BD) depression is sparse. The aims of the study were to assess the neurocognitive profiles in treatment-resistant, acutely admitted BD depression inpatients, to compare the neurocognitive functioning in patients with BD I and II, and to identify the demographic and clinical illness characteristics associated with cognitive functioning.
methodsAcutely admitted BD I (n = 19) and BD II (n = 32) inpatients who fulfilled the DSM-IV-TR criteria for a major depressive episode were tested with the MATRICS Consensus Cognitive Battery (MCCB), the Wechsler Abbreviated Scale of Intelligence, the National Adult Reading Test, and a battery of clinical measures.
resultsNeurocognitive impairments were evident in the BD I and BD II depression inpatients within all MCCB domains. The numerical scores on all MCCB-measures were lower in the BD I group than in the BD II group, with a significant difference on one of the measures, category fluency. 68.4% of the BD I patients had clinically significant impairment (>1.5 SD below normal mean) in two or more domains compared to 37.5% of the BD II patients (p = 0.045). A significant reduction in IQ from the premorbid to the current level was seen in BD I but not BD II patients. Higher age was associated with greater neurocognitive deficits compared to age-adjusted published norms.
conclusionsA high proportion of patients with therapy-resistant BD I or II depression exhibited global neurocognitive impairments with clinically significant severity. The cognitive impairments were more common in BD I compared to BD II patients, particularly processing speed. These findings suggest that clinicians should be aware of the severe neurocognitive dysfunction in treatment-resistant bipolar depression, particularly in BD I.
trial registrationNCT00664976.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.